Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

INTRODUCTION: Immunotherapy targeting the programmed cell death protein–1 (PD-1) axis elicits durable antitumor responses in multiple cancer types. However, clinical responses vary, and biomarkers predictive of response may help to identify patients who will derive the greatest therapeutic benefit....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Science
Autors principals: Cristescu, Razvan, Mogg, Robin, Ayers, Mark, Albright, Andrew, Murphy, Erin, Yearley, Jennifer, Sher, Xinwei, Liu, Xiao Qiao, Lu, Hongchao, Nebozhyn, Michael, Zhang, Chunsheng, Lunceford, Jared K., Joe, Andrew, Cheng, Jonathan, Webber, Andrea L., Ibrahim, Nageatte, Plimack, Elizabeth R., Ott, Patrick A., Seiwert, Tanguy Y., Ribas, Antoni, McClanahan, Terrill K., Tomassini, Joanne E., Loboda, Andrey, Kaufman, David
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718162/
https://ncbi.nlm.nih.gov/pubmed/30309915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.aar3593
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars